Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]Stone R. Search for sepsis drugs goes on despite past failures. Science 264, 365-367 (1994)

  • [2]Warren HS. Strategies for the treatment of sepsis. N Engl J Med 336, 952-953 (1997)

  • [3]Wiens MO, Kumbakumba E, Kissoon N, Ansermino JM, Ndamira A, Larson CP. Pediatric sepsis in the developing world: challenges in defining sepsis and issues in post-discharge mortality. Clin Epidemiol 4, 319-325 (2012)

  • [4]Carcillo JA. Reducing the global burden of sepsis in infants and children: a clinical practice research agenda. Pediatr Crit Care Med 6, S157-164 (2005)

  • [5]Bahl R, Martines J, Ali N, Bhan MK, Carlo W, Chan KY. Research priorities to reduce global mortality from newborn infections by 2015. Pediatr Infect Dis J 28, S43-48 (2009)

  • [6]Hood JL, Emeson RB. Editing of neurotransmitter receptor and ion channel RNAs in the nervous system. Curr Top Microbiol Immunol 353, 61-90 (2012)

  • [7]Toth AM, Zhang P, Das S, George CX, Samuel CE. Interferon action and the double-stranded RNA-dependent enzymes ADAR1 adenosine deaminase and PKR protein kinase. Prog Nucleic Acid Res Mol Biol 81, 369-434 (2006)

  • [8]Nie Y, Hammond GL, Yang JH. Double-stranded RNA deaminase ADAR1 increases host susceptibility to virus infection. J Virol 81, 917-923 (2007)

  • [9]Bass BL, Weintraub H, Cattaneo R, Billeter MA. Biased hypermutation of viral RNA genomes could be due to unwinding/modification of double-stranded RNA. Cell 56, 331 (1989)

  • [10]Cattaneo R, Billeter MA. Mutations and A/I hypermutations in measles virus persistent infections. Curr Top Microbiol Immunol 176, 63-74 (1992)

  • [11]Hundley HA, Bass BL. ADAR editing in double-stranded UTRs and other noncoding RNA sequences. Trends Biochem Sci 35, 377-383 (2010)

  • [12]Jin Y, Zhang W, Li Q. Origins and evolution of ADAR-mediated RNA editing. IUBMB Life 61, 572-578 (2009).

  • [13]Nishikura K. Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem 79, 321-349 (2010)

  • [14]Chen CX, Cho DS, Wang Q, Lai F, Carter KC, Nishikura K. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA 6, 755-767 (2000)

  • [15]Melcher T, Maas S, Herb A, Sprengel R, Higuchi M, Seeburg PH. RED2, a brain-specific member of the RNA-specific adenosine deaminase family. J Biol Chem 271, 31795-31798 (1996)

  • [16]Bass BL. RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem 71, 817-846 (2002)

  • [17]Dawson TR, Sansam CL, Emeson RB. Structure and sequence determinants required for the RNA editing of ADAR2 substrates. J Biol Chem 279, 4941-4951 (2004)

  • [18]Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 14, 778-809, table of contents (2001)

  • [19]Patterson JB, Samuel CE. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol Cell Biol 15, 5376-5388 (1995)

  • [20]Hartner JC, Schmittwolf C, Kispert A, Muller AM, Higuchi M, Seeburg PH. Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. J Biol Chem 279, 4894-4902 (2004)

  • [21]Wang Q, Miyakoda M, Yang W, Khillan J, Stachura DL, Weiss MJ, et al. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J Biol Chem 279, 4952-4961 (2004)

  • [22]Seeburg PH, Hartner J. Regulation of ion channel/neurotransmitter receptor function by RNA editing. Curr Opin Neurobiol 13, 279-283 (2003)

  • [23]Oldstone MB. Modeling subacute sclerosing panencephalitis in a transgenic mouse system: uncoding pathogenesis of disease and illuminating components of immune control. Curr Top Microbiol Immunol 330, 31-54 (2009)

  • [24]Ramaswami G, Lin W, Piskol R, Tan MH, Davis C, Li JB. Accurate identification of human Alu and non-Alu RNA editing sites.Nat Methods 9, 579-581 (2012)

  • [25]Wu D, Lamm AT, Fire AZ. Competition between ADAR and RNAi pathways for an extensive class of RNA targets. Nat Struct Mol Biol 18, 1094-1101 (2011)

  • [26]Kawahara Y, Megraw M, Kreider E, Iizasa H, Valente L, Hatzigeorgiou AG. Frequency and fate of microRNA editing in human brain. Nucleic Acids Res 36, 5270-5280 (2008)

  • [27]Kawahara Y, Zinshteyn B, Chendrimada TP, Shiekhattar R, Nishikura K. RNA editing of the microRNA-151 precursor blocks cleavage by the Dicer-TRBP complex. EMBO Rep 8, 763-769 (2007)

  • [28]Iizasa H, Wulff BE, Alla NR, Maragkakis M, Megraw M, Hatzigeorgiou A. Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. J Biol Chem 285, 33358-33370 (2010)

  • [29]Kawahara Y, Zinshteyn B, Sethupathy P, Iizasa H, Hatzigeorgiou AG, Nishikura K. Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. Science 315, 1137-1140 (2007)

  • [30]Ota H, Sakurai M, Gupta R, Valente L, Wulff BE, Ariyoshi K. ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencing. Cell 153, 575-589 (2013)

  • [31]Cho DS, Yang W, Lee JT, Shiekhattar R, Murray JM, Nishikura K. Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. J Biol Chem 278, 17093-17102 (2003)

  • [32]Nishikura K. Editor meets silencer: crosstalk between RNA editing and RNA interference. Nat Rev Mol Cell Biol 7, 919-931 (2006)

  • [33]Sharp TV, Moonan F, Romashko A, Joshi B, Barber GN, Jagus R. The vaccinia virus E3L gene product interacts with both the regulatory and the substrate binding regions of PKR: implications for PKR autoregulation. Virology 250, 302-315 (1998)

  • [34]Patterson JB, Thomis DC, Hans SL, Samuel CE. Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. Virology 210, 508-511 (1995)

  • [35]Rabinovici R, Kabir K, Chen M, Su Y, Zhang D, Luo X. ADAR1 is involved in the development of microvascular lung injury. Circ Res 88, 1066-1071 (2001)

  • [36]Patterson JB, Cornu TI, Redwine J, Dales S, Lewicki H, Holz A. Evidence that the hypermutated M protein of a subacute sclerosing panencephalitis measles virus actively contributes to the chronic progressive CNS disease. Virology 291, 215-225 (2001)

  • [37]Wong TC, Ayata M, Hirano A, Yoshikawa Y, Tsuruoka H, Yamanouchi K. Generalized and localized biased hypermutation affecting the matrix gene of a measles virus strain that causes subacute sclerosing panencephalitis. J Virol 63, 5464-5468 (1989)

  • [38]Wong TC, Ayata M, Ueda S, Hirano A. Role of biased hypermutation in evolution of subacute sclerosing panencephalitis virus from progenitor acute measles virus. J Virol 65, 2191-2199 (1991)

  • [39]Cattaneo R. Biased (A-->I) hypermutation of animal RNA virus genomes. Curr Opin Genet Dev 4, 895-900 (1994)

  • [40]Cattaneo R, Schmid A, Eschle D, Baczko K, ter Meulen V, Billeter MA. Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Cell 55, 255-265 (1988)

  • [41]Martinez I, Dopazo J, Melero JA. Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. J Gen Virol 78 ( Pt 10), 2419-2429 (1997)

  • [42]Tenoever BR, Ng SL, Chua MA, McWhirter SM, Garcia-Sastre A, Maniatis T. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 315, 1274-1278 (2007)

  • [43]Zahn RC, Schelp I, Utermohlen O, von Laer D. A-to-G hypermutation in the genome of lymphocytic choriomeningitis virus. J Virol 81, 457-464 (2007)

  • [44]Hartwig D, Schutte C, Warnecke J, Dorn I, Hennig H, Kirchner H. The large form of ADAR 1 is responsible for enhanced hepatitis delta virus RNA editing in interferon-alpha-stimulated host cells. J Viral Hepat 13, 150-157 (2006)

  • [45]Jayan GC, Casey JL. Increased RNA editing and inhibition of hepatitis delta virus replication by high-level expression of ADAR1 and ADAR2. J Virol 76, 3819-3827 (2002)

  • [46]Taylor DR, Puig M, Darnell ME, Mihalik K, Feinstone SM. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. J Virol 79, 6291-6298 (2005)

  • [47]Chang J, Gudima SO, Taylor JM. Evolution of hepatitis delta virus RNA genome following long-term replication in cell culture. J Virol 79, 13310-13316 (2005)

  • [48]Dabo S, Meurs EF. dsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection. Viruses 4, 2598-2635 (2012)

  • [49]Garcia MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 70, 1032-1060 (2006)

  • [50]Sadler AJ, Williams BR. Structure and function of the protein kinase R. Curr Top Microbiol Immunol 316, 253-292 (2007)

  • [51]Bonnet MC, Daurat C, Ottone C, Meurs EF. The N-terminus of PKR is responsible for the activation of the NF-kappaB signaling pathway by interacting with the IKK complex. Cell Signal 18, 1865-1875 (2006)

  • [52]Gil J, Garcia MA, Gomez-Puertas P, Guerra S, Rullas J, Nakano H. TRAF family proteins link PKR with NF-kappa B activation. Mol Cell Biol 24, 4502-4512 (2004).

  • [53]Clerzius G, Gelinas JF, Daher A, Bonnet M, Meurs EF, Gatignol A. ADAR1 interacts with PKR during human immunodeficiency virus infection of lymphocytes and contributes to viral replication. J Virol 83, 10119-10128 (2009)

  • [54]Daher A, Longuet M, Dorin D, Bois F, Segeral E, Bannwarth S. Two dimerization domains in the trans-activation response RNA-binding protein (TRBP) individually reverse the protein kinase R inhibition of HIV-1 long terminal repeat expression. J Biol Chem 276, 33899-33905 (2001)

  • [55]Dimitrova DI, Yang X, Reichenbach NL, Karakasidis S, Sutton RE, Henderson EE. Lentivirus-mediated transduction of PKR into CD34(+) hematopoietic stem cells inhibits HIV-1 replication in differentiated T cell progeny. J Interferon Cytokine Res 25, 345-360 (2005)

  • [56]Clerzius G, Gelinas JF, Gatignol A. Multiple levels of PKR inhibition during HIV-1 replication. Rev Med Virol 21, 42-53 (2011).

  • [57]Jagus R, Gray MM. Proteins that interact with PKR. Biochimie 76, 779-791 (1994)

  • [58]Der SD, Yang YL, Weissmann C, Williams BR. A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc Natl Acad Sci U S A 94, 3279-3283 (1997)

  • [59]Williams BR. Signal integration via PKR. Sci STKE 2001, re2 (2001)

  • [60]Roberts A, Kretzschmar E, Perkins AS, Forman J, Price R, Buonocore L. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 72, 4704-4711 (1998)

  • [61]Schnell MJ, Buonocore L, Kretzschmar E, Johnson E, Rose JK. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A 93, 11359-11365 (1996)

  • [62]Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29, 1303-1310 (2001)

  • [63]Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34, 344-353 (2006)

  • [64]Brun-Buisson C, Meshaka P, Pinton P, Vallet B. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 30, 580-588 (2004)

  • [65]Deitch EA. Animal models of sepsis and shock: a review and lessons learned. Shock 9, 1-11 (1998)

  • [66]O’Reilly M, Newcomb DE, Remick D. Endotoxin, sepsis, and the primrose path. Shock 12, 411-420 (1999)

  • [67]Bhat N, Wright JG, Broder KR, Murray EL, Greenberg ME, Glover MJ. Influenza-associated deaths among children in the United States, 2003-2004.N Engl J Med 353, 2559-2567 (2005)

  • [68]Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 8, CD004879 (2012)

  • [69]Jefferson T, Smith S, Demicheli V, Harnden A, Rivetti A, Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 365, 773-780 (2005)

  • [70]Chong DC, Raboni SM, Abujamra KB, Marani DM, Nogueira MB, Tsuchiya LR. Respiratory viruses in pediatric necropsies: an immunohistochemical study. Pediatr Dev Pathol 12, 211-216 (2009)

  • [71]Garcia Garcia ML, Ordobas Gabin M, Calvo Reya C, Gonzalez Alvarez M, Aguilar Ruiz J, Arregui Sierra A. (Viral infection of the lower respiratory tract in hospitalized infants: etiology, clinical features and risk factors). An Esp Pediatr 55, 101-107 (2001)

  • [72]Wagner T. Bronchiolitis. Pediatr Rev 30, 386-395; quiz 395 (2009)

  • [73]Bronchiolitis. AAoPSoDaMo. Diagnosis and management of bronchiolitis. Pediatrics 118, 1774-1793 (2006)

  • [74]Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med 96 Suppl B, S1-7 (2002)

  • [75]Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 113, 701-707 (2004)

  • [76]Finelli L, Fiore A, Dhara R, Brammer L, Shay DK, Kamimoto L. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics 122, 805-811 (2008)

  • [77]Randolph AG, Vaughn F, Sullivan R, Rubinson L, Thompson BT, Yoon G. Critically ill children during the 2009-2010 influenza pandemic in the United States. Pediatrics 128, e1450-1458 (2011)

  • [78]Hall MW, Geyer SM, Guo CY, Panoskaltsis-Mortari A, Jouvet P, Ferdinands J. Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med 41, 224-236 (2013)

  • [79]Kimberlin DW. Herpes simplex virus infections in neonates and early childhood. Semin Pediatr Infect Dis 16, 271-281 (2005)

  • [80]Sharp J, Harrison CJ, Puckett K, Selvaraju SB, Penaranda S, Nix WA. Characteristics of young infants in whom human parechovirus, enterovirus or neither were detected in cerebrospinal fluid during sepsis evaluations. Pediatr Infect Dis J 32, 213-216 (2013)

  • [81]Verboon-Maciolek MA, Krediet TG, Gerards LJ, de Vries LS, Groenendaal F, van Loon AM. Severe neonatal parechovirus infection and similarity with enterovirus infection. Pediatr Infect Dis J 27, 241-245 (2008)

  • [82]Hatherill M. Sepsis predisposition in children with human immunodeficiency virus. Pediatr Crit Care Med 6, S92-98 (2005)

  • [83]Stanberry LR, Floyd-Reising SA, Connelly BL, Alter SJ, Gilchrist MJ, Rubio C. Herpes simplex viremia: report of eight pediatric cases and review of the literature. Clin Infect Dis 18, 401-407 (1994)

  • [84]Steiner I, Aebi C, Ridolfi Luthy A, Wagner B, Leibundgut K. Fatal adenovirus hepatitis during maintenance therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 50, 647-649 (2008)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Mar 2017Review

Assessing the potential function of ADAR1 in virus-associated sepsis

Yugang Zhuang 1, Hu Peng 1, Yuanzhuo Chen 1, Shuqin Zhou 1, Yanqing Chen 1,*
Affiliation
Article Info

1 Emergency Department, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, No 301, Mid Yangchang Road, Shanghai, China

Abstract

Sepsis syndrome is a common and frequently fatal clinical condition. It is defined by the presence of both infection and an uncontrolled systemic inflammatory response. It represents a major, although largely unappreciated, healthcare problem worldwide. It is especially problematic in infants and toddlers who show markedly increased susceptibility to severe infections caused by various pathogens, including viruses. Viruses are important causative agents of sepsis. Host adenosine deaminase acting on RNA 1 (ADAR1) catalyzes adenosine to inosine (A-to-I) editing of RNA transcripts, thus changing viral RNAs and exerting antiviral and proviral effects. In addition, ADAR1 promotes viral replication by directly interacting with protein kinase R and suppressing its kinase activity. We here discuss the function of ADAR1 and its regulatory role in viral infection. Further, we establish the relationship between ADAR1 and virus-associated sepsis, thus providing an important basis for the development of novel therapeutic targets for the treatment of virus-associated sepsis.

Keywords

  • ADAR1
  • Sepsis
  • Virus
  • HSV
  • HIV-1
  • Review

References